Neuraxis announces new submission to the fda for the expansion of its ib-stim label; provides compliance with nyse guidelines on audit disclosure

Carmel, ind., june 07, 2024 (globe newswire) -- neuraxis, inc. (“neuraxis,” or the “company”) (nyse american: nrxs), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced a submission to the fda for expansion of its ib-stim label. the new submission is significant as it would allow access to a larger patient population beyond 11-18 years of age and allow for marketing of 4 devices per prescription.
NRXS Ratings Summary
NRXS Quant Ranking